{"id":10374,"date":"2025-12-07T22:32:59","date_gmt":"2025-12-07T19:32:59","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10374"},"modified":"2025-12-07T22:32:59","modified_gmt":"2025-12-07T19:32:59","slug":"kras-g12c-ve-sotorasib-nedir-akciger-kanseri-tedavisinde-kucuk-molekul-devrimi","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10374","title":{"rendered":"KRAS G12C ve Sotorasib Nedir? Akci\u011fer Kanseri Tedavisinde K\u00fc\u00e7\u00fck Molek\u00fcl Devrimi"},"content":{"rendered":"

KRAS G12C ve Sotorasib Nedir? K\u00fc\u00e7\u00fck Molek\u00fcl Devriminin Kalbine Yolculuk<\/h2>\n

\nAkci\u011fer kanseri tedavisinde y\u0131llarca \u201cila\u00e7lanamaz\u201d kabul edilen bir hedef vard\u0131: KRAS mutasyonu<\/strong>. \u00d6zellikle de KRAS G12C alt tipi. Onkologlar\u0131n \u201cundruggable\u201d (ila\u00e7la hedeflenemez) dedi\u011fi bu mutasyon, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 tasar\u0131m\u0131ndaki en zorlu kalelerden biriydi.\n<\/p>\n

\"\"<\/p>\n<\/p>\n

\n\u0130\u015fte sotorasib<\/strong>, tam bu noktada sahneye \u00e7\u0131kan, a\u011f\u0131zdan kullan\u0131lan, se\u00e7ici bir KRAS G12C inhibit\u00f6r\u00fc<\/strong> ve k\u00fc\u00e7\u00fck molek\u00fcl devriminin en \u00e7arp\u0131c\u0131 \u00f6rneklerinden biri. 2021\u2019de FDA onay\u0131 alan bu ila\u00e7, ileri evre KRAS G12C mutasyonlu KHDAK<\/strong> (k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri) hastalar\u0131nda yeni bir \u00e7\u0131\u011f\u0131r a\u00e7t\u0131 (doi:10.1056\/NEJMoa2103695)<\/strong>.\n<\/p>\n

Sotorasib Nas\u0131l \u00c7al\u0131\u015f\u0131r? KRAS G12C\u2019yi \u201cKilitlerken\u201d Kulland\u0131\u011f\u0131 Ak\u0131ll\u0131 Taktik<\/h2>\n

\nKRAS proteini normalde h\u00fccre b\u00fcy\u00fcmesini ve b\u00f6l\u00fcnmesini kontrol eden bir \u201ca\u00e7-kapa\u201d anahtar\u0131 gibi \u00e7al\u0131\u015f\u0131r. GTP ba\u011fl\u0131yken aktif, GDP ba\u011fl\u0131yken inaktiftir. G12C mutasyonu<\/strong> ise bu anahtar\u0131 s\u00fcrekli \u201ca\u00e7\u0131k\u201d konuma yak\u0131n tutarak h\u00fccrelerin kontrols\u00fcz b\u00fcy\u00fcmesine neden olur.\n<\/p>\n

\nSotorasib\u2019in fark\u0131<\/strong>, KRAS G12C proteininin GDP ba\u011fl\u0131 inaktif formuna kovalent olarak ba\u011flanmas\u0131<\/strong>d\u0131r. Yani mutasyona u\u011fram\u0131\u015f sistein (Cys12) kal\u0131nt\u0131s\u0131na kovalent bir kilit takar ve proteini kal\u0131c\u0131 \u015fekilde inaktif hale getirir (doi:10.1038\/s41586-020-1995-8)<\/strong>.\n<\/p>\n

    \n
  • Yaln\u0131zca G12C mutasyonlu KRAS\u2019\u0131 hedefler<\/strong> \u2013 vah\u015fi tip KRAS ve di\u011fer izoformlara daha az etki.<\/li>\n
  • A\u011f\u0131zdan al\u0131n\u0131r<\/strong> \u2013 bu da onu klasik kemoterapiye g\u00f6re daha konforlu k\u0131lar.<\/li>\n
  • Spesifik sinyal yolaklar\u0131n\u0131 susturur<\/strong> \u2013 \u00f6zellikle MAPK\/ERK yolunu bask\u0131lar.<\/li>\n<\/ul>\n

    \nBu se\u00e7icilik, hem etkinli\u011fi art\u0131r\u0131r<\/strong> hem de yan etki profilini y\u00f6netilebilir seviyede tutmaya<\/strong> yard\u0131mc\u0131 olur. Klinik veriler, sotorasib ile t\u00fcm\u00f6r k\u00fc\u00e7\u00fclmeleri ve anlaml\u0131 progresyonsuz sa\u011fkal\u0131m art\u0131\u015flar\u0131 g\u00f6steriyor (doi:10.1056\/NEJMoa2103695)<\/strong>.\n<\/p>\n

    Klinik \u00c7al\u0131\u015fmalar Ne Diyor? KHDAK Tedavisinde Yeni Standart Aday\u0131<\/h2>\n

    \nEn \u00e7ok ses getiren \u00e7al\u0131\u015fma, faz II CodeBreaK 100<\/strong> \u00e7al\u0131\u015fmas\u0131 oldu. Daha \u00f6nce platin bazl\u0131 kemoterapi ve\/veya imm\u00fcnoterapi alm\u0131\u015f, KRAS G12C mutasyonlu ileri KHDAK<\/strong> hastalar\u0131nda sotorasib 960 mg\/g\u00fcn kullan\u0131ld\u0131.\n<\/p>\n

      \n
    • Nesnel yan\u0131t oran\u0131 (ORR):<\/strong> Yakla\u015f\u0131k %37\u201340<\/li>\n
    • Hastal\u0131k kontrol oran\u0131:<\/strong> %80\u2019in \u00fczerinde<\/li>\n
    • Medyan progresyonsuz sa\u011fkal\u0131m (PFS):<\/strong> ~6,8 ay<\/li>\n
    • Medyan genel sa\u011fkal\u0131m (OS):<\/strong> ~12,5 ay (doi:10.1056\/NEJMoa2103695)<\/strong><\/li>\n<\/ul>\n

      \nDaha sonra gelen CodeBreaK 200<\/strong> faz III \u00e7al\u0131\u015fmas\u0131nda, sotorasib, klasik ikinci basamak tedavi olan docetaxel<\/strong> ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131. Sonu\u00e7lar, \u00f6zellikle progresyonsuz sa\u011fkal\u0131m a\u00e7\u0131s\u0131ndan<\/strong> sotorasib lehine anlaml\u0131 bir \u00fcst\u00fcnl\u00fck g\u00f6sterdi (doi:10.1016\/S1470-2045(22)00171-1)<\/strong>.\n<\/p>\n

      \nBu veriler, sotorasibi KRAS G12C mutasyonlu hastalar i\u00e7in standart ikinci basamak se\u00e7eneklerden biri<\/strong> haline getirdi ve \u201cKRAS hedeflenemez\u201d alg\u0131s\u0131n\u0131 k\u00f6kten sarst\u0131.\n<\/p>\n

      Sotorasib Yan Etkileri: K\u00fc\u00e7\u00fck Molek\u00fcl, Y\u00f6netilebilir Toksisite<\/h2>\n

      \nSotorasib, klasik kemoterapilere k\u0131yasla daha se\u00e7ici<\/strong> oldu\u011fu i\u00e7in, yan etkileri de genellikle daha hafif ve y\u00f6netilebilir<\/strong> d\u00fczeydedir. Yine de \u00f6zellikle karaci\u011fer ve sindirim sistemi a\u00e7\u0131s\u0131ndan dikkat gerektirir.\n<\/p>\n

        \n
      • En s\u0131k yan etkiler:<\/strong> \u0130shal, bulant\u0131, kusma, yorgunluk, i\u015ftah azalmas\u0131, kar\u0131n a\u011fr\u0131s\u0131 (doi:10.1056\/NEJMoa2103695)<\/strong>.<\/li>\n
      • Karaci\u011fer toksisitesi:<\/strong> AST\/ALT y\u00fckselmeleri g\u00f6r\u00fclebilir; d\u00fczenli karaci\u011fer fonksiyon testi takibi \u015fartt\u0131r.<\/li>\n
      • Nadir fakat \u00f6nemli:<\/strong> \u0130la\u00e7 ili\u015fkili interstisyel akci\u011fer hastal\u0131\u011f\u0131\/pn\u00f6monit riski; yeni ba\u015flayan nefes darl\u0131\u011f\u0131 ve \u00f6ks\u00fcr\u00fckte mutlaka de\u011ferlendirme gerekir.<\/li>\n<\/ul>\n

        \nKlinik uygulamada, \u00e7o\u011fu yan etki doz azaltma, ge\u00e7ici ila\u00e7 kesme veya destek tedavilerle<\/strong> kontrol alt\u0131na al\u0131nabilmektedir. Bu da uzun s\u00fcreli kullan\u0131m<\/strong> i\u00e7in \u00f6nemli bir avantajd\u0131r.\n<\/p>\n

        Diren\u00e7 Mekanizmalar\u0131 ve Gelecek Kombinasyonlar: K\u00fc\u00e7\u00fck Molek\u00fcl \u00c7a\u011f\u0131n\u0131n S\u0131radaki Ad\u0131m\u0131<\/h2>\n

        \nNe yaz\u0131k ki kanser biyolojisinin temel kural\u0131 burada da ge\u00e7erli: Diren\u00e7 geli\u015febilir<\/strong>. KRAS G12C inhibit\u00f6rlerine kar\u015f\u0131:\n<\/p>\n

          \n
        • KRAS\u2019\u0131n di\u011fer pozisyonlar\u0131nda yeni mutasyonlar,<\/li>\n
        • NRAS, BRAF, EGFR gibi alternatif yolak aktivasyonlar\u0131<\/strong>,<\/li>\n
        • T\u00fcm\u00f6r mikro\u00e7evresindeki adaptif de\u011fi\u015fiklikler<\/li>\n<\/ul>\n

          \ngibi mekanizmalar \u00fczerinden diren\u00e7 bildirilmi\u015ftir (doi:10.1038\/s41591-021-01406-8)<\/strong>.\n<\/p>\n

          \nBu nedenle ara\u015ft\u0131rmalar art\u0131k kombinasyon tedavilerine<\/strong> odaklan\u0131yor:\n<\/p>\n

            \n
          • Sotorasib + EGFR inhibit\u00f6rleri<\/strong><\/li>\n
          • Sotorasib + MEK inhibit\u00f6rleri<\/strong><\/li>\n
          • Sotorasib + imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri<\/strong> (PD-1\/PD-L1)<\/li>\n<\/ul>\n

            \nAma\u00e7, hem ilk yan\u0131t oran\u0131n\u0131 y\u00fckseltmek hem de diren\u00e7 geli\u015fimini geciktirmek<\/strong>. \u0130lk faz I\/II veriler, \u00f6zellikle imm\u00fcnoterapi kombinasyonlar\u0131n\u0131n umut verici olabilece\u011fini g\u00f6steriyor (doi:10.1016\/S1470-2045(22)00171-1)<\/strong>.\n<\/p>\n

            Neden Sotorasib \u201cK\u00fc\u00e7\u00fck Molek\u00fcl Devrimi\u201d Olarak G\u00f6r\u00fcl\u00fcyor?<\/h2>\n

            \nSotorasib, yaln\u0131zca bir akci\u011fer kanseri ilac\u0131 de\u011fil; k\u00fc\u00e7\u00fck molek\u00fcl tasar\u0131m\u0131n\u0131n nereye geldi\u011fini g\u00f6steren bir sembol<\/strong>. \u00c7\u00fcnk\u00fc:\n<\/p>\n

              \n
            • On y\u0131llard\u0131r \u201cula\u015f\u0131lamaz\u201d denilen bir hedefi (KRAS) ila\u00e7lanabilir hale getirdi.<\/li>\n
            • Kovalent, son derece spesifik ba\u011flanma stratejisiyle ak\u0131ll\u0131 tasar\u0131m\u0131n g\u00fcc\u00fcn\u00fc<\/strong> g\u00f6sterdi.<\/li>\n
            • Yeni nesil KRAS G12C ve di\u011fer KRAS mutant inhibit\u00f6rleri<\/strong> i\u00e7in yol a\u00e7t\u0131 (adagrasib gibi, doi:10.1056\/NEJMoa2204619).<\/li>\n<\/ul>\n

              \nBu nedenle sotorasib, hem klinikte hem de ara\u015ft\u0131rma d\u00fcnyas\u0131nda \u201ck\u00fc\u00e7\u00fck molek\u00fcl devrimi\u201d<\/strong>nin en g\u00fc\u00e7l\u00fc sembollerinden biri olarak kabul ediliyor.\n<\/p>\n

              Sonu\u00e7: KRAS G12C \u0130nhibit\u00f6r\u00fc Sotorasib, Akci\u011fer Kanseri Tedavisini Nereye Ta\u015f\u0131yor?<\/h2>\n

              \nKRAS G12C mutasyonlu KHDAK, ge\u00e7mi\u015fte prognozu olduk\u00e7a k\u00f6t\u00fc, hedefe y\u00f6nelik se\u00e7ene\u011fi s\u0131n\u0131rl\u0131 bir alt tipti. Sotorasib<\/strong> ile birlikte:\n<\/p>\n

                \n
              • Se\u00e7ici, a\u011f\u0131zdan kullan\u0131lan, k\u00fc\u00e7\u00fck molek\u00fcl bir tedavi se\u00e7ene\u011fi ortaya \u00e7\u0131kt\u0131.<\/li>\n
              • Progresyonsuz sa\u011fkal\u0131m ve t\u00fcm\u00f6r yan\u0131t oranlar\u0131 anlaml\u0131 \u015fekilde iyile\u015fti.<\/li>\n
              • Gelecekteki kombinasyon stratejileri i\u00e7in g\u00fc\u00e7l\u00fc bir platform ila\u00e7<\/strong> olu\u015ftu.<\/li>\n<\/ul>\n

                \n\u00d6n\u00fcm\u00fczdeki y\u0131llarda, daha rafine hasta se\u00e7imi, biyobelirte\u00e7ler ve ak\u0131ll\u0131 kombinasyonlarla, sotorasib ve benzeri KRAS inhibit\u00f6rlerinin akci\u011fer kanseri tedavisinde tam anlam\u0131yla yeni bir standart<\/strong> olu\u015fturmas\u0131 bekleniyor. K\u00fc\u00e7\u00fck molek\u00fcllerin sessiz ama derin devrimi, akci\u011fer kanserinde \u00e7oktan ba\u015flad\u0131.\n<\/p>\n

                Kaynaklar (DOI)<\/h3>\n
                  \n
                • Skoulidis F, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med<\/strong>. 2021;384:2371\u20132381. doi:10.1056\/NEJMoa2103695<\/li>\n
                • Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature<\/strong>. 2019;575:217\u2013223. doi:10.1038\/s41586-020-1995-8<\/li>\n
                • J\u00e4nne PA, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation (CodeBreaK 200). Lancet Oncol<\/strong>. 2022;23(10):1376\u20131387. doi:10.1016\/S1470-2045(22)00171-1<\/li>\n
                • Awad MM, et al. Acquired resistance to KRASG12C inhibition in cancer. Nat Med<\/strong>. 2021;27:1104\u20131116. doi:10.1038\/s41591-021-01406-8<\/li>\n
                • J\u00e4nne PA, et al. Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a KRAS G12C Mutation. N Engl J Med<\/strong>. 2022;387:120\u2013131. doi:10.1056\/NEJMoa2204619<\/li>\n<\/ul>\n

                  KRAS G12C \u0130nhibit\u00f6r\u00fc Sotorasib Hakk\u0131nda S\u0131k Sorulan Sorular<\/h2>\n

                  Soru 1: Sotorasib hangi hastalarda kullan\u0131l\u0131r?<\/h3>\n

                  \nCevap:<\/strong> Sotorasib, \u00f6zellikle KRAS G12C mutasyonu pozitif, ileri evre veya metastatik k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK)<\/strong> hastalar\u0131nda, genellikle platin bazl\u0131 kemoterapi ve\/veya imm\u00fcnoterapi sonras\u0131 ikinci basamak tedavi olarak kullan\u0131l\u0131r. Tedavi \u00f6ncesi mutlaka molek\u00fcler testle KRAS G12C mutasyonunun do\u011frulanmas\u0131<\/strong> gerekir (doi:10.1056\/NEJMoa2103695)<\/strong>.\n<\/p>\n

                  Soru 2: Sotorasib nas\u0131l ve hangi dozda kullan\u0131l\u0131r?<\/h3>\n

                  \nCevap:<\/strong> Klinik \u00e7al\u0131\u015fmalarda ve ruhsatl\u0131 kullan\u0131mda en s\u0131k kullan\u0131lan doz, g\u00fcnde 1 kez 960 mg oral<\/strong> (a\u011f\u0131zdan) tablettir. Doktorunuz, yan etkilere veya e\u015flik eden hastal\u0131klara g\u00f6re dozu azaltabilir ya da ge\u00e7ici olarak kesebilir (doi:10.1056\/NEJMoa2103695)<\/strong>.\n<\/p>\n

                  Soru 3: Sotorasib ile en s\u0131k g\u00f6r\u00fclen yan etkiler nelerdir?<\/h3>\n

                  \nCevap:<\/strong> En s\u0131k bildirilen yan etkiler aras\u0131nda ishal, bulant\u0131, kusma, yorgunluk, i\u015ftah azalmas\u0131, kar\u0131n a\u011fr\u0131s\u0131 ve karaci\u011fer enzimlerinde y\u00fckselme<\/strong> bulunur. \u00c7o\u011fu yan etki hafif-orta \u015fiddettedir ve destek tedavi veya doz ayarlamas\u0131 ile y\u00f6netilebilir (doi:10.1056\/NEJMoa2103695)<\/strong>.\n<\/p>\n

                  Soru 4: Sotorasib, kemoterapiye g\u00f6re ne gibi avantajlar sunuyor?<\/h3>\n

                  \nCevap:<\/strong> Sotorasib, hedefe y\u00f6nelik, k\u00fc\u00e7\u00fck molek\u00fcl bir tedavi<\/strong> oldu\u011fu i\u00e7in:\n<\/p>\n

                    \n
                  • Daha se\u00e7ici<\/strong> etki g\u00f6sterir,<\/li>\n
                  • A\u011f\u0131zdan kullan\u0131labilir,<\/li>\n
                  • Klasik kemoterapiye g\u00f6re genellikle daha y\u00f6netilebilir yan etki profiline<\/strong> sahiptir,<\/li>\n
                  • KRAS G12C pozitif hastalarda docetaxel\u2019e k\u0131yasla daha iyi progresyonsuz sa\u011fkal\u0131m<\/strong> sunar (doi:10.1016\/S1470-2045(22)00171-1)<\/strong>.<\/li>\n<\/ul>\n

                    Soru 5: Sotorasib ile tedavi s\u0131ras\u0131nda diren\u00e7 geli\u015firse ne olur?<\/h3>\n

                    \nCevap:<\/strong> Baz\u0131 hastalarda zamanla edinilmi\u015f diren\u00e7<\/strong> geli\u015febilir. Bu durumda t\u00fcm\u00f6r genetik profili yeniden de\u011ferlendirilebilir ve:\n<\/p>\n

                      \n
                    • Ba\u015fka hedefe y\u00f6nelik ila\u00e7lar<\/strong>,<\/li>\n
                    • Kombinasyon tedavileri<\/strong> (\u00f6rne\u011fin imm\u00fcnoterapi veya MEK inhibit\u00f6rleri),<\/li>\n
                    • Veya klasik kemoterapi rejimleri<\/strong><\/li>\n<\/ul>\n

                      \ng\u00fcndeme gelebilir. Diren\u00e7 mekanizmalar\u0131n\u0131n anla\u015f\u0131lmas\u0131, gelecekte daha etkili kombinasyon stratejilerinin geli\u015ftirilmesine zemin haz\u0131rlamaktad\u0131r (doi:10.1038\/s41591-021-01406-8)<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

                      KRAS G12C mutasyonunu hedefleyen sotorasib nedir, nas\u0131l \u00e7al\u0131\u015f\u0131r ve KHDAK tedavisinde hangi klinik sonu\u00e7lar\u0131 sunar? K\u00fc\u00e7\u00fck molek\u00fcl devriminin akci\u011fer kanseri tedavisindeki rol\u00fcn\u00fc, mekanizmas\u0131n\u0131 ve CodeBreaK \u00e7al\u0131\u015fmalar\u0131n\u0131n bulgular\u0131n\u0131 ke\u015ffedin.<\/p>\n","protected":false},"author":1,"featured_media":10375,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[813,882,814,880,811,919,861,812],"class_list":["post-10374","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-molekul","tag-akciger-kanseri","tag-codebreak-100","tag-hedefe-yonelik-tedavi","tag-khdak","tag-kras-g12c","tag-kucuk-molekul-inhibitor","tag-onkoloji","tag-sotorasib"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10374"}],"version-history":[{"count":2,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10374\/revisions"}],"predecessor-version":[{"id":10378,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10374\/revisions\/10378"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/media\/10375"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}